MGMT and neoplasm: Among the tumor-specific epigenetic signatures, analyses of four methylation-silenced genes in a large series of patients of laryngeal and hypopharyngeal cancer shows that hypermethylation in promoter regions of MGMT (90%), DAPK (death-associated protein kinase) (91%) and CDH1 (E-cadherin) (81%) (but not p16) is a frequent event, although not predictive of mortality or second primary cancer [63].